Loading
Resistance Training / Obesity (BMI>30) / Dual GIP/GLP-1 Receptor Agonist Tirzepatide · Phase 4 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 4 trial registered to evaluate whether resistance training can preserve contractile thigh muscle volume in patients treated with tirzepatide for obesity. No results have been posted in this registry record; the study addresses a mechanistically plausible concern that rapid weight loss from GIP/GLP-1 agonists may be accompanied by clinically significant muscle loss.
Phase 4, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Obesity (BMI>30); age from 18 Years; to 60 Years. Intervention: Dual GIP/GLP-1 Receptor Agonist Tirzepatide + Resistance Tr…. Compared with: Dual GIP/GLP-1 Receptor Agonist Tirzepatide — Active Comparator. n = 150. 1 site: Germany.
This is a planned Phase 4 trial registered to evaluate whether resistance training can preserve contractile thigh muscle volume in patients treated with tirzepatide for obesity. No results have been posted in this registry record; the study addresses a mechanistically plausible concern that rapid weight loss from GIP/GLP-1 agonists may be accompanied by clinically significant muscle loss.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If positive, this trial could establish resistance training as a standard adjunct to GIP/GLP-1 agonist therapy to mitigate weight-loss-associated muscle loss. However, results are not yet available; clinicians should await completion and publication before modifying practice.
This is a Phase 4 interventional trial registration with no results posted; it describes a planned study of resistance training to mitigate muscle loss during tirzepatide treatment, addressing a plausible but unproven clinical question.
As stated by the source record.
Quoted from the source exactly as published.
If positive, this trial could establish resistance training as a standard adjunct to GIP/GLP-1 agonist therapy to mitigate weight-loss-associated muscle loss. However, results are not yet available; clinicians should await completion and publication before modifying practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07777575). This is a study registration, not published results. Lead sponsor: Technical University of Munich. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 150 participants (ESTIMATED). Conditions: Obesity (BMI>30). Interventions: DRUG: Dual GIP/GLP-1 Receptor Agonist Tirzepatide; BEHAVIORAL: Resistance Training. Primary outcome measures: Change in contractile thigh muscle volume (mL), as assessed by magnetic resonance imaging (MRI) , From baseline to the end of treatment at 24 weeks. Brief summary: Incretin-based pharmacotherapies induce significant weight loss and represent a paradigm shift in obesity treatment. However, particularly fast weight loss may be accompanied by a significant loss of muscle mass, which is associated with a reduced metabolic rate at rest and during physical activity, increased insulin resistance, limited mobility, and potential long-term adverse effects. The aim of this clinical trial is to examine the effects of resistance training versus standard of care on contractile thigh muscle volume in patients receiving the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists 'tirzepatide'.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.